MX2019006098A - Ensayo de anticuerpos. - Google Patents
Ensayo de anticuerpos.Info
- Publication number
- MX2019006098A MX2019006098A MX2019006098A MX2019006098A MX2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A
- Authority
- MX
- Mexico
- Prior art keywords
- test sample
- liver cancer
- mammalian subject
- antibody
- detecting
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619954.9A GB201619954D0 (en) | 2016-11-25 | 2016-11-25 | Antibody assay |
| PCT/GB2017/053541 WO2018096351A1 (en) | 2016-11-25 | 2017-11-24 | Antibody assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006098A true MX2019006098A (es) | 2019-12-02 |
Family
ID=58073509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006098A MX2019006098A (es) | 2016-11-25 | 2017-11-24 | Ensayo de anticuerpos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190376975A1 (https=) |
| EP (1) | EP3545309B1 (https=) |
| JP (1) | JP7249284B2 (https=) |
| KR (1) | KR20190088510A (https=) |
| CN (2) | CN108107218B (https=) |
| AU (1) | AU2017365931A1 (https=) |
| BR (1) | BR112019010636A2 (https=) |
| CA (1) | CA3044492A1 (https=) |
| GB (1) | GB201619954D0 (https=) |
| IL (1) | IL266857A (https=) |
| MX (1) | MX2019006098A (https=) |
| RU (1) | RU2769987C2 (https=) |
| WO (1) | WO2018096351A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109116023B (zh) * | 2018-06-14 | 2021-06-04 | 郑州大学第一附属医院 | 一种肺癌标志物抗-mmp12自身抗体及其应用 |
| CN109709335B (zh) * | 2018-12-18 | 2020-10-27 | 中国医学科学院基础医学研究所 | 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用 |
| CN109633165B (zh) * | 2018-12-18 | 2021-03-09 | 中国医学科学院基础医学研究所 | 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用 |
| ES3039706T3 (en) * | 2019-02-19 | 2025-10-24 | Otsuka Denshi Kk | Method for determining condition parameters for photodynamic therapy and photodynamic therapy apparatus |
| CN110579611B (zh) * | 2019-09-18 | 2023-01-31 | 郑州大学 | 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法 |
| JPWO2022118947A1 (https=) * | 2020-12-04 | 2022-06-09 | ||
| CN114994318A (zh) * | 2022-06-16 | 2022-09-02 | 深圳上泰生物工程有限公司 | 一种用于检测akr1b10的试剂盒及其制备方法 |
| CN116444680B (zh) * | 2022-12-28 | 2024-05-03 | 杭州凯保罗生物科技有限公司 | 一种ralgds-krt8-aif1融合肿瘤抗原蛋白的制备方法及其应用 |
| CN119639903B (zh) * | 2025-01-17 | 2025-11-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于肝内胆管癌的生物标记物、药物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387881B2 (en) * | 2001-09-19 | 2008-06-17 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the liver |
| ITPD20030264A1 (it) * | 2003-10-30 | 2005-04-30 | Xeptagen Spa | Metodo di diagnosi altamente specifico per neoplasie |
| TWI281473B (en) * | 2003-12-19 | 2007-05-21 | Ind Tech Res Inst | Biomarkers for liver diseases and method for using same |
| CN1632589A (zh) * | 2003-12-24 | 2005-06-29 | 财团法人工业技术研究院 | 肝脏疾病的生物标记分子及其检测方法 |
| US20080254481A1 (en) * | 2006-11-13 | 2008-10-16 | Invitrogen Corporation | Methods and kits for detecting prostate cancer biomarkers |
| CN102301237B (zh) * | 2008-12-02 | 2014-05-14 | 财团法人工业技术研究院 | 用于肝纤维化诊断的生物标记 |
| CN102356316B (zh) * | 2009-03-05 | 2015-07-08 | 独立行政法人产业技术综合研究所 | 肝内胆管癌的检出、辨别方法 |
| US20120309034A1 (en) * | 2010-02-12 | 2012-12-06 | Nitto Boseki Co., Ltd. | METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME |
| CN102175864A (zh) * | 2011-01-19 | 2011-09-07 | 江苏永鼎股份有限公司 | 一组早期肝癌分子标志物及其应用 |
| CN102507938B (zh) * | 2011-10-08 | 2014-12-24 | 复旦大学附属中山医院 | 一种肝癌转移预测定量抗体芯片及试剂盒 |
| US20150185226A1 (en) * | 2012-07-23 | 2015-07-02 | Inserm (Institut National De La Sante Et La Recherche Medicale) | Method for Diagnosing Scleroderma |
| JP2014240771A (ja) * | 2013-06-11 | 2014-12-25 | 日東紡績株式会社 | Ｋｕ７０／Ｋｕ８６ヘテロダイマーに対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法 |
| GB201320061D0 (en) * | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| GB201411060D0 (en) * | 2014-06-20 | 2014-08-06 | Oncimmune Ltd | Improved immunoassay method |
| TWI700493B (zh) * | 2014-07-02 | 2020-08-01 | 香港商龍勝發展有限公司 | 用於非侵入性肝癌診斷之特異性生物標記組 |
| CN104990905B (zh) * | 2015-06-30 | 2017-12-29 | 曲凯 | 一种基于固相酶联免疫荧光斑点的肝癌转移诊断试剂盒 |
-
2016
- 2016-11-25 GB GBGB1619954.9A patent/GB201619954D0/en not_active Ceased
-
2017
- 2017-11-24 WO PCT/GB2017/053541 patent/WO2018096351A1/en not_active Ceased
- 2017-11-24 JP JP2019548777A patent/JP7249284B2/ja active Active
- 2017-11-24 EP EP17807913.3A patent/EP3545309B1/en active Active
- 2017-11-24 CA CA3044492A patent/CA3044492A1/en not_active Abandoned
- 2017-11-24 AU AU2017365931A patent/AU2017365931A1/en not_active Abandoned
- 2017-11-24 US US16/463,549 patent/US20190376975A1/en active Pending
- 2017-11-24 RU RU2019118625A patent/RU2769987C2/ru active
- 2017-11-24 MX MX2019006098A patent/MX2019006098A/es unknown
- 2017-11-24 KR KR1020197018129A patent/KR20190088510A/ko not_active Withdrawn
- 2017-11-24 BR BR112019010636-7A patent/BR112019010636A2/pt active IP Right Grant
- 2017-11-27 CN CN201711213227.4A patent/CN108107218B/zh active Active
- 2017-11-27 CN CN202110715736.7A patent/CN113655224A/zh active Pending
-
2019
- 2019-05-23 IL IL266857A patent/IL266857A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108107218B (zh) | 2021-10-08 |
| JP7249284B2 (ja) | 2023-03-30 |
| WO2018096351A1 (en) | 2018-05-31 |
| CN108107218A (zh) | 2018-06-01 |
| JP2020515826A (ja) | 2020-05-28 |
| RU2019118625A3 (https=) | 2021-03-31 |
| CA3044492A1 (en) | 2018-05-31 |
| EP3545309A1 (en) | 2019-10-02 |
| AU2017365931A1 (en) | 2019-06-06 |
| RU2019118625A (ru) | 2020-12-25 |
| GB201619954D0 (en) | 2017-01-11 |
| US20190376975A1 (en) | 2019-12-12 |
| KR20190088510A (ko) | 2019-07-26 |
| IL266857A (en) | 2019-07-31 |
| RU2769987C2 (ru) | 2022-04-12 |
| EP3545309B1 (en) | 2021-03-31 |
| CN113655224A (zh) | 2021-11-16 |
| BR112019010636A2 (pt) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006098A (es) | Ensayo de anticuerpos. | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| MX377315B (es) | Predicción in vitro de semivida in vivo de anticuerpos. | |
| EA202090290A1 (ru) | ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР | |
| EA201492105A1 (ru) | Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1 | |
| JOP20200216A1 (ar) | تجارب للكشف عن التنكس العصبي | |
| EA201370063A1 (ru) | Фосфолипидом рака | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| EA201992748A1 (ru) | Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EP3907509A3 (en) | Diagnosis of early stage pancreatic cancer | |
| MX2022002138A (es) | Estandares de antigeno prostatico y sus usos. | |
| MX358772B (es) | Metodo para detectar cancer. | |
| EA201792289A1 (ru) | Способы обнаружения агглютинации и композиции для их осуществления | |
| MX2022013738A (es) | Ensayo de anticuerpos neutralizantes para proteinas terapeuticas. | |
| MX377026B (es) | Biomarcadores para la progresión de enfermedades en melanoma. | |
| MX2020009363A (es) | Un método para detectar magea4. | |
| MX384485B (es) | Deteccion temprana de preeclampsia. | |
| MX2019000591A (es) | Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma. | |
| MX2019003288A (es) | Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. | |
| MX2018015047A (es) | Metodo para la deteccion de un anticuerpo igm especifico para un flavivirus en una muestra. | |
| EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
| BR112018076005A2 (pt) | anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral |